TL;DR
CJC-1295 (No DAC version) is a modified Growth Hormone-Releasing Hormone (GHRH) analog consisting of the first 29 amino acids of native GHRH with four amino acid substitutions that confer resistance to DPP-IV enzymatic degradation, substantially extending half-life compared with native GHRH. It is one of the most frequently researched tools in somatotropic axis investigation.
Research use only. CJC-1295 has not received FDA approval for any human therapeutic indication and is sold strictly for in-vitro laboratory research purposes.
What is CJC-1295?
CJC-1295 (No DAC version) is a modified Growth Hormone-Releasing Hormone (GHRH) analog consisting of the first 29 amino acids of native GHRH with four amino acid substitutions that confer resistance to DPP-IV enzymatic degradation, substantially extending half-life compared with native GHRH. It is one of the most frequently researched tools in somatotropic axis investigation.
Research-grade CJC-1295 is supplied as a lyophilized powder with batch-specific Certificate of Analysis verification at ≥99% purity by HPLC.
Molecular Properties
| Property | Value |
|---|---|
| Molecular formula | Modified GRF(1-29) |
| Molecular weight | 3,367.9 (No DAC) g/mol |
| Amino acid count | 29 |
| Purity standard | ≥99% (HPLC verified) |
| Lyophilized storage | -20°C, 24–36 months |
| Reconstitution vehicle | Bacteriostatic water (primary), 0.6% acetic acid or saline (alternative) |
Proposed Mechanisms of Action
Published preclinical research has proposed several complementary mechanisms through which CJC-1295 may exert observed effects in laboratory models. No single mechanism has been fully validated in human contexts.
GHRH receptor agonism
CJC-1295 binds the GHRH receptor on pituitary somatotrophs, triggering cAMP-mediated GH synthesis and release.
DPP-IV resistance via modified amino acids
Four strategic substitutions (D-Ala at position 2, others) may modulate DPP-IV cleavage, extending half-life from ~7 minutes (native GHRH) to ~30 minutes (No DAC) or ~8 days (DAC version).
Synergistic signaling with GHS
When combined with ghrelin receptor agonists (Ipamorelin, GHRP-6), produces supra-additive GH release due to dual-pathway activation.
Research Applications
Pulsatile GH release research
Pharmacokinetic and pharmacodynamic studies of GH pulse amplitude and frequency under various dosing schedules.
GHRH + GHS combination research
The classic research pairing: CJC-1295 + Ipamorelin for examining synergistic somatotropic activation.
IGF-1 and downstream tissue research
Studies examining hepatic IGF-1 production and peripheral tissue responses to sustained GH elevation.
Storage and Reconstitution
- Lyophilized at -20°C in original sealed vial; typical shelf life 24–36 months.
- Reconstitution with bacteriostatic water (0.9% benzyl alcohol) is standard. Alternative vehicles include sterile saline or dilute acetic acid depending on experimental requirements.
- Reconstituted solution stored at 2–8°C, used within 7–28 days.
- Avoid repeated freeze-thaw of reconstituted peptide.
- Handling: Follow institutional biosafety protocols; use only in qualified research settings.
Regulatory Considerations
As of early 2026, CJC-1295 has no investigational human therapeutic indication. The peptide continues to be available for strictly in-vitro research purposes when properly labeled, sold to qualified researchers, and handled under appropriate institutional biosafety protocols. Researchers should consult current FDA guidance and institutional policies before acquiring any research peptide.
Research Gaps
Despite the substantial published literature on CJC-1295:
- Human pharmacokinetic and pharmacodynamic data remains limited.
- Proposed mechanisms require further validation in human-relevant systems.
- Long-term safety data across species is incomplete.
- Dose-response optimization for specific research applications continues to be an active research question.
- Independent cross-laboratory replication of specific findings is uneven across the literature.
These gaps represent ongoing research opportunities for careful, well-designed preclinical investigation using research-grade material with verified Certificate of Analysis.
Frequently Asked Questions
Is CJC-1295 approved for human use?
No. CJC-1295 has no investigational therapeutic indication. It is sold exclusively for in-vitro laboratory research in qualified research settings.
What purity standard should research-grade CJC-1295 meet?
Quality research-grade material should be ≥99% purity as verified by HPLC with a batch-specific Certificate of Analysis. Aureum Peptides provides COAs with every shipment and maintains a searchable COA portal.
How is CJC-1295 typically reconstituted for research?
Bacteriostatic water is the most common reconstitution vehicle. Alternative vehicles (sterile saline, dilute acetic acid) may be used depending on specific experimental protocols.
How long is reconstituted CJC-1295 stable?
Once reconstituted, the peptide is generally stored at 2–8°C and used within 7–28 days depending on specific handling and vehicle. Avoid repeated freeze-thaw cycles.
Where can I verify the Certificate of Analysis for my batch?
Aureum Peptides includes a batch-specific COA with every shipment and maintains an online COA portal accessible using the batch number printed on your vial.
References
- Teichman SL et al. J Clin Endocrinol Metab. 2006.
- Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006.
- Sackmann-Sala L et al. 2009.
- Alba M et al. Endocrinology. 2006.
- Jette L et al. Endocrinology. 2005.
(Reference list abbreviated. Full bibliography with DOIs available on request.)
Shop Research-Grade CJC-1295
Order research-grade CJC-1295 from Aureum Peptides: CJC-1295 product page
All peptides ship with batch-specific Certificate of Analysis, ≥99% purity verification, and cold-chain logistics. Same-day dispatch on orders placed before 2:00 PM EST.
Disclaimer: This article summarizes published preclinical research for educational purposes to support qualified research activities. The information herein does not constitute research information, therapeutic claims, or recommendations for human use. CJC-1295 is not approved by the FDA for any therapeutic indication. Always consult institutional policies and applicable regulations when conducting research with peptides.
Last reviewed: 2026-04-21
Author: Aureum Peptides Scientific Writing Team
Category: Somatotropic Research
Tags: CJC-1295, GHRH analog, growth hormone, modified GRF
